SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #12 Increased Dynamics of Novel A6/B Recombinant Forms Emergence Following Full-Scale War in Ukraine - Karol SerwinView Slideset
MOMartin ObermeierMDSlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #11 Early Treatment Failure with Lenacapavir in HIV-2 Infection - Martin ObermeierView Slideset
MZMaurizio ZazziPhDSlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Andrea de Luca Lecture: Biomedical Innovations in Drug Resistance Interpretation - Maurizio ZazziView Slideset
FCFrancesca Ceccherini-SilbersteinPhDSlidesetHIVViral Hepatitis and Liver Disease23rd European Meeting on HIV & Hepatitis 2025How to Improve Fruitful Dialogue between the Virology Lab and Clinicians: Lab Manager Perspective - Francesca Ceccherini-SilbersteinView Slideset
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #10 Resistance Analyses of F/TAF, F/TDF, and Lenacapavir in the PURPOSE 1 and 2 Studies – Stephanie CoxView Slideset
AMAnne-Geneviève MarcelinMDSlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #9 Clearance of NNRTI Resistance-Associated Mutations in the HIV-1 DNA Reservoir with or Without the Presence of M184V Mutation - Anne-Geneviève MarcelinView Slideset
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #8 Analysis of 16 Years of ARV Resistance Transmission in Newly Diagnosed HIV Cases in Spain (2007-2023): 2023 Update and the Impact of PrEP on M184V Detection - Paloma MuñozView Slideset
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #7 Resistance Analysis of Long-Acting Lenacapavir in Heavily Treatment-Experienced People with HIV After 3 Years of Lenacapavir Treatment - Nicolas MargotView Slideset
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #6 Lenacapavir Resistance Profile in Heavily Treatment-Experienced People in the PRESTIGIO Registry - Maria Mercedes SantoroView Slideset
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #5 A French National Real-World Survey of People with Multi-Resistant HIV-1 Viruses Treated with an Antiretroviral Regimen Including Fostemsavir or Ibalizumab - Charlotte CharpentierView Slideset
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #4 WG-am: A Novel Antiviral Dipeptide from Elite Controllers as a Promising Vaginal Microbicide for HIV Prevention - Rafael Ceña DiezView Slideset
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #3 Unveiling Novel Microbiome Signatures for Natural Virological Control in HIV-1 Elite Controllers - Xiangning BaiView Slideset
